| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
I confirmed suppressive effect of Semicarbazide-sensitive mono-amine oxidase (SSAO) inhibitor on cataract formation in two animal models. (1) In the chick embryo model of steroid-induced cataract, administration of SSAO inhibitor decreased the lens opacity (lens opacity score: 3.47 ± 0.97 versus 2.80 ± 1.00, p = 0.016), and recovered the amounts of reduced glutathione in lens (3.98 ± 0.68 nmol / lens versus 4.88 ± 0.88 nmol / lens, p< 0.001). (2) In the streptozotocin (STZ) induced diabetic rat model, administration of SSAO inhibitor by eye drops suppressed diabetic cataract formation. In control group lens opacity scores were 2.28 ± 1.07 at 7 weeks, 2.89 ± 1.16 at 9 weeks, and 3.56 ± 0.51 at 12 weeks after STZ injection. In treated group lens opacity scores were 1.33 ± 1.32 (p = 0.023) at 7 weeks, 1.78 ± 1.15 (p = 0.017) at 9 weeks, and 3.28 ± 1.02 (p = 0.668) at 12 weeks after STZ injection, administration of SSAO inhibitors decreased the lens opacity at 7 and 9 weeks.
|
